What are the major opportunities in the Non-Alcoholic Steatohepatitis (NASH) market? What are the strategies for the Non-Alcoholic Steatohepatitis (NASH) market?

For detailed insights on the major opportunities and strategies in the Non-Alcoholic Steatohepatitis (NASH) market, Read More

How does the Non-Alcoholic Steatohepatitis (NASH) market relate to the overall economy and other similar markets?

For detailed insights on Non-Alcoholic Steatohepatitis (NASH)'s relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Non-Alcoholic Steatohepatitis (NASH) market growth? SWOT analysis of the Non-Alcoholic Steatohepatitis (NASH) market.

For detailed insights on the key dynamics influencing the Non-Alcoholic Steatohepatitis (NASH) market growth and SWOT analysis of the Non-Alcoholic Steatohepatitis (NASH) industry, Read More

Non-Alcoholic Steatohepatitis (NASH) Market Global Report 2026 Market Report Infographic Image

Item added to cart!

Published : January 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF

Purchase This Report

Non-Alcoholic Steatohepatitis (NASH) Market Report 2026

Name: Non-Alcoholic Steatohepatitis (NASH) Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Global Outlook – By Dosage Form (Solid, Liquid), By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products), By Disease Cause (Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity), By Sales Channel (Hospital Pharmacy, Retail Pharmacy, Online Provider), By Application (Oral, Parenteral) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Non-Alcoholic Steatohepatitis (NASH) Market Overview

• Non-Alcoholic Steatohepatitis (NASH) market size has reached to $6.06 billion in 2025

• Expected to grow to $24.32 billion in 2030 at a compound annual growth rate (CAGR) of 31.9%

• Growth Driver: The Growing Demand For NASH Treatment Amid Obesity Epidemic

• Market Trend: Innovative Therapeutic Approaches for Liver Health

• North America was the largest region in 2025.

What Is Covered Under Non-Alcoholic Steatohepatitis (NASH) Market?

Non-alcoholic steatohepatitis (NASH) is a severe case of fatty liver disease that is characterized by inflammation of the liver and can proceed to cirrhosis and liver failure.

The main types of non-alcoholic steatohepatitis (NASH) are solid and liquid. Solid is primarily created as crystalline solid forms that are sold as tablets for oral consumption, due to its excellent purity and durability. The products involved are vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib, and cenicriviroc, and others that are used for different disease causes such as hypertension, heart disease, high blood lipid, type 2 diabetes, obesity, and sold by the hospital pharmacy, retail pharmacy, online providers. It includes oral and parenteral applications.

Non-Alcoholic Steatohepatitis (NASH) Market Global Report 2026 Market Report bar graph

What Is The Non-Alcoholic Steatohepatitis (NASH) Market Size and Share 2026?

The non-alcoholic steatohepatitis (nash) market size has grown exponentially in recent years. It will grow from $6.06 billion in 2025 to $8.04 billion in 2026 at a compound annual growth rate (CAGR) of 32.7%. The growth in the historic period can be attributed to limited awareness about nash, lack of effective treatment options, reliance on lifestyle modifications, high prevalence of metabolic disorders, fragmented market landscape.

What Is The Non-Alcoholic Steatohepatitis (NASH) Market Growth Forecast?

The non-alcoholic steatohepatitis (nash) market size is expected to see exponential growth in the next few years. It will grow to $24.32 billion in 2030 at a compound annual growth rate (CAGR) of 31.9%. The growth in the forecast period can be attributed to advancements in targeted therapies, increased healthcare expenditure, growing adoption of non-invasive diagnostics, expansion of pharmaceutical pipelines, rising collaborations for r&d. Major trends in the forecast period include rising prevalence of obesity and type 2 diabetes, development of non-invasive diagnostic tools, increasing research in liver fibrosis therapies, growth in personalized and targeted drug treatments, expansion of hospital and retail pharmacy networks.

Book your 30 minutes free consultation with our research experts

Global Non-Alcoholic Steatohepatitis (NASH) Market Segmentation

1) By Dosage Form: Solid, Liquid

2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products

3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity

4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider

5) By Application: Oral, Parenteral

Subsegments:

1) By Solid: Tablets, Capsules, Other Solid Dosage Forms

2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms

What Is The Driver Of The Non-Alcoholic Steatohepatitis (NASH) Market?

The rising cases of obesity is driving the demand for the non-alcoholic steatohepatitis (NASH) market going forward. Obesity is an aberrant or excessive fat build-up that poses a health concern, as well as body weight that is higher than what is deemed healthy or typical for a person of a specific height. As non-alcoholic fatty liver disease has become more prevalent due to the rising obesity pandemic, NASH may become the most widespread cause of severe liver disease in the ensuing decades, therefore, driving need for NASH treatment and related drugs. For instance, in May 2025, according to the Government Digital Service, a UK-based government body, In 2023 to 2024, the prevalence of overweight (including obesity) in adults was higher among men (69.7%) than women (59.2%), while the prevalence of obesity in adults was higher among women (26.9%) than men (26.2%). Therefore, the rise in the cases of obesity will drive the growth of the non-alcoholic steatohepatitis (NASH) industry.

Key Players In The Global Non-Alcoholic Steatohepatitis (NASH) Market

Major companies operating in the non-alcoholic steatohepatitis (nash) market are NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens

Global Non-Alcoholic Steatohepatitis (NASH) Market Trends and Insights

Major companies operating in the non-alcoholic steatohepatitis (NASH) market are developing thyroid hormone receptor-beta (THR-beta) agonists to enhance liver metabolism, reduce liver fat accumulation, and improve liver function. Thyroid hormone receptor-beta (THR-beta) agonists are compounds that selectively activate the thyroid hormone receptor-beta subtype, which is a key receptor involved in the regulation of metabolism, growth, and development. For instance, in March 2024, the Food and Drug Administration, a US-based regulatory body, approved Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist as the first treatment for adults with noncirrhotic NASH with moderate to advanced liver scarring (fibrosis). By selectively activating the THR-beta receptor, Rezdiffra helps regulate lipid metabolism, leading to a reduction in intrahepatic triglycerides and overall liver fat accumulation.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis (NASH) Market?

In April 2024, Novo Nordisk A/S, a Denmark-based global healthcare company, formed research collaborations with Omega Therapeutics and Cellarity to explore novel treatment approaches for cardiometabolic diseases. The collaboration aims to accelerate the discovery and development of innovative therapies targeting metabolic and cardiovascular conditions, enhancing patient outcomes while fostering innovation and growth in the cardiometabolic disease space. Omega Therapeutics is a US-based biotechnology company specializing in gene control therapeutics, and Cellarity is a US-based biotech firm focused on cell reprogramming-based drug discovery.

Regional Insights

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Non-Alcoholic Steatohepatitis (NASH) Market?

The non-alcoholic steatohepatitis (NASH) market consists of sales of drugs that are used for the treatment of non-alcoholic fatty liver diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Non-Alcoholic Steatohepatitis (NASH) Market Report 2026?

The non-alcoholic steatohepatitis (nash) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis (nash) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Non-Alcoholic Steatohepatitis (NASH) Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$8.04 billion
Revenue Forecast In 2035	$24.32 billion
Growth Rate	CAGR of 32.7% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Dosage Form, Product, Disease Cause, Sales Channel, Application
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Intercept Pharmaceuticals Inc., Enanta Pharmaceutical
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Non-Alcoholic Steatohepatitis (NASH) Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Non-Alcoholic Steatohepatitis (NASH) Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Non-Alcoholic Steatohepatitis (NASH) Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Non-Alcoholic Steatohepatitis (NASH) Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Digitalization, Cloud, Big Data & Cybersecurity

4.1.3 Artificial Intelligence & Autonomous Intelligence

4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.1.5 Industry 4.0 & Intelligent Manufacturing

4.2. Major Trends

4.2.1 Rising Prevalence Of Obesity And Type 2 Diabetes

4.2.2 Development Of Non-Invasive Diagnostic Tools

4.2.3 Increasing Research In Liver Fibrosis Therapies

4.2.4 Growth In Personalized And Targeted Drug Treatments

4.2.5 Expansion Of Hospital And Retail Pharmacy Networks

5. Non-Alcoholic Steatohepatitis (NASH) Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Specialty Clinics

5.3 Diagnostic Centers

5.4 Retail Pharmacies

5.5 Online Pharmacies

6. Non-Alcoholic Steatohepatitis (NASH) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Non-Alcoholic Steatohepatitis (NASH) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Non-Alcoholic Steatohepatitis (NASH) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Non-Alcoholic Steatohepatitis (NASH) Market Size, Comparisons And Growth Rate Analysis

7.3. Global Non-Alcoholic Steatohepatitis (NASH) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Non-Alcoholic Steatohepatitis (NASH) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Non-Alcoholic Steatohepatitis (NASH) Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Non-Alcoholic Steatohepatitis (NASH) Market Segmentation

9.1. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Solid, Liquid

9.2. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products

9.3. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity

9.4. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacy, Retail Pharmacy, Online Provider

9.5. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Oral, Parenteral

9.6. Global Non-Alcoholic Steatohepatitis (NASH) Market, Sub-Segmentation Of Solid, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Tablets, Capsules, Other Solid Dosage Forms

9.7. Global Non-Alcoholic Steatohepatitis (NASH) Market, Sub-Segmentation Of Liquid, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms

10. Non-Alcoholic Steatohepatitis (NASH) Market Regional And Country Analysis

10.1. Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market

11.1. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Non-Alcoholic Steatohepatitis (NASH) Market

12.1. China Non-Alcoholic Steatohepatitis (NASH) Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Non-Alcoholic Steatohepatitis (NASH) Market

13.1. India Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Non-Alcoholic Steatohepatitis (NASH) Market

14.1. Japan Non-Alcoholic Steatohepatitis (NASH) Market Overview

14.2. Japan Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Non-Alcoholic Steatohepatitis (NASH) Market

15.1. Australia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market

16.1. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Non-Alcoholic Steatohepatitis (NASH) Market

17.1. South Korea Non-Alcoholic Steatohepatitis (NASH) Market Overview

17.2. South Korea Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Non-Alcoholic Steatohepatitis (NASH) Market

18.1. Taiwan Non-Alcoholic Steatohepatitis (NASH) Market Overview

18.2. Taiwan Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Non-Alcoholic Steatohepatitis (NASH) Market

19.1. South East Asia Non-Alcoholic Steatohepatitis (NASH) Market Overview

19.2. South East Asia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market

20.1. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market Overview

20.2. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Non-Alcoholic Steatohepatitis (NASH) Market

21.1. UK Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Non-Alcoholic Steatohepatitis (NASH) Market

22.1. Germany Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Non-Alcoholic Steatohepatitis (NASH) Market

23.1. France Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Non-Alcoholic Steatohepatitis (NASH) Market

24.1. Italy Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Non-Alcoholic Steatohepatitis (NASH) Market

25.1. Spain Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market

26.1. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market Overview

26.2. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Non-Alcoholic Steatohepatitis (NASH) Market

27.1. Russia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Non-Alcoholic Steatohepatitis (NASH) Market

28.1. North America Non-Alcoholic Steatohepatitis (NASH) Market Overview

28.2. North America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Non-Alcoholic Steatohepatitis (NASH) Market

29.1. USA Non-Alcoholic Steatohepatitis (NASH) Market Overview

29.2. USA Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Non-Alcoholic Steatohepatitis (NASH) Market

30.1. Canada Non-Alcoholic Steatohepatitis (NASH) Market Overview

30.2. Canada Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Non-Alcoholic Steatohepatitis (NASH) Market

31.1. South America Non-Alcoholic Steatohepatitis (NASH) Market Overview

31.2. South America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Non-Alcoholic Steatohepatitis (NASH) Market

32.1. Brazil Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Non-Alcoholic Steatohepatitis (NASH) Market

33.1. Middle East Non-Alcoholic Steatohepatitis (NASH) Market Overview

33.2. Middle East Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Non-Alcoholic Steatohepatitis (NASH) Market

34.1. Africa Non-Alcoholic Steatohepatitis (NASH) Market Overview

34.2. Africa Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Segmentation By Product, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Non-Alcoholic Steatohepatitis (NASH) Market Regulatory and Investment Landscape

36. Non-Alcoholic Steatohepatitis (NASH) Market Competitive Landscape And Company Profiles

36.1. Non-Alcoholic Steatohepatitis (NASH) Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Non-Alcoholic Steatohepatitis (NASH) Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Non-Alcoholic Steatohepatitis (NASH) Market Company Profiles

36.3.1. NGM Biopharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

36.3.3. AstraZeneca plc. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. GlaxoSmithKline plc. Overview, Products and Services, Strategy and Financial Analysis

36.3.5. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

37. Non-Alcoholic Steatohepatitis (NASH) Market Other Major And Innovative Companies

The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc.

38. Global Non-Alcoholic Steatohepatitis (NASH) Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis (NASH) Market

40. Non-Alcoholic Steatohepatitis (NASH) Market High Potential Countries, Segments and Strategies

40.1 Non-Alcoholic Steatohepatitis (NASH) Market In 2030 - Countries Offering Most New Opportunities

40.2 Non-Alcoholic Steatohepatitis (NASH) Market In 2030 - Segments Offering Most New Opportunities

40.3 Non-Alcoholic Steatohepatitis (NASH) Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Non-Alcoholic Steatohepatitis (NASH) Market, Overview Of Key Products - Product Examples

Table 2: Global Non-Alcoholic Steatohepatitis (NASH) Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Non-Alcoholic Steatohepatitis (NASH) Market, Supply Chain Analysis

Table 4: Global Non-Alcoholic Steatohepatitis (NASH) Market, Major Raw Material Providers

Table 5: Global Non-Alcoholic Steatohepatitis (NASH) Market, Major Resource Providers

Table 6: Global Non-Alcoholic Steatohepatitis (NASH) Market, Major Manufacturers (Suppliers)

Table 7: Global Non-Alcoholic Steatohepatitis (NASH) Market, Major Distributors And Channel Partners

Table 8: Global Non-Alcoholic Steatohepatitis (NASH) Market, Key Technologies & Future Trends

Table 9: Global Non-Alcoholic Steatohepatitis (NASH) Market, Major Trends

Table 10: Global Non-Alcoholic Steatohepatitis (NASH) Market, Major End Users

Table 11: Global Non-Alcoholic Steatohepatitis (NASH) Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Non-Alcoholic Steatohepatitis (NASH) Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Non-Alcoholic Steatohepatitis (NASH) Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Non-Alcoholic Steatohepatitis (NASH) Market - TAM, US$ Billion, 2025

Table 15: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Non-Alcoholic Steatohepatitis (NASH) Market, Sub-Segmentation Of Solid, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global Non-Alcoholic Steatohepatitis (NASH) Market, Sub-Segmentation Of Liquid, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Asia-Pacific, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Asia-Pacific, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: Asia-Pacific, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: China, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: China, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: China, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: India, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: India, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: India, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: Japan, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: Japan, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Japan, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Australia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Australia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Australia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Indonesia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Indonesia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Indonesia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: South Korea, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: South Korea, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: South Korea, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: Taiwan, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: Taiwan, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: Taiwan, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: South East Asia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: South East Asia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: South East Asia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: Western Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: Western Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: Western Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: UK, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: UK, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: UK, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: Germany, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: Germany, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: Germany, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: France, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: France, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: France, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: Italy, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: Italy, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: Italy, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Spain, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Spain, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Spain, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Eastern Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Eastern Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Eastern Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Russia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Russia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: Russia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: North America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: North America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: North America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: USA, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: USA, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: USA, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: Canada, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: Canada, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: Canada, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: South America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: South America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: South America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: Brazil, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: Brazil, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: Brazil, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Middle East, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Middle East, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Middle East, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Africa, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Africa, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Africa, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 96: Global Non-Alcoholic Steatohepatitis (NASH) Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 97: Global Non-Alcoholic Steatohepatitis (NASH) Market - Company Scoring Matrix

Table 98: NGM Biopharmaceuticals Inc. Financial Performance

Table 99: Novartis AG Financial Performance

Table 100: AstraZeneca plc. Financial Performance

Table 101: GlaxoSmithKline plc. Financial Performance

Table 102: F. Hoffmann-La Roche AG Financial Performance

Table 103: Global Non-Alcoholic Steatohepatitis (NASH) Market, Competitive Benchmarking (In USD Billions)

Table 104: Global Non-Alcoholic Steatohepatitis (NASH) Market, Competitive Dashboard

Table 105: Global Non-Alcoholic Steatohepatitis (NASH) Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 106: Global, Non-Alcoholic Steatohepatitis (NASH) Market Size Gain ($ Billion), Segmentation By Dosage Form, 2025 – 2030

Table 107: Global, Non-Alcoholic Steatohepatitis (NASH) Market Size Gain ($ Billion), Segmentation By Product, 2025 – 2030

Table 108: Global, Non-Alcoholic Steatohepatitis (NASH) Market Size Gain ($ Billion), Segmentation By Disease Cause, 2025 – 2030

List Of Figures

Figure 1: Global Non-Alcoholic Steatohepatitis (NASH) Market, Overview Of Key Products - Product Examples

Figure 2: Global Non-Alcoholic Steatohepatitis (NASH) Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Non-Alcoholic Steatohepatitis (NASH) Market, Supply Chain Analysis

Figure 4: Global Non-Alcoholic Steatohepatitis (NASH) Market, Major Raw Material Providers

Figure 5: Global Non-Alcoholic Steatohepatitis (NASH) Market, Major Resource Providers

Figure 6: Global Non-Alcoholic Steatohepatitis (NASH) Market, Major Manufacturers (Suppliers)

Figure 7: Global Non-Alcoholic Steatohepatitis (NASH) Market, Major Distributors And Channel Partners

Figure 8: Global Non-Alcoholic Steatohepatitis (NASH) Market, Key Technologies & Future Trends

Figure 9: Global Non-Alcoholic Steatohepatitis (NASH) Market, Major Trends

Figure 10: Global Non-Alcoholic Steatohepatitis (NASH) Market, Major End Users

Figure 11: Global Non-Alcoholic Steatohepatitis (NASH) Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Non-Alcoholic Steatohepatitis (NASH) Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Non-Alcoholic Steatohepatitis (NASH) Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Non-Alcoholic Steatohepatitis (NASH) Market - TAM, US$ Billion, 2025

Figure 15: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Non-Alcoholic Steatohepatitis (NASH) Market, Sub-Segmentation Of Solid, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global Non-Alcoholic Steatohepatitis (NASH) Market, Sub-Segmentation Of Liquid, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Asia-Pacific, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Asia-Pacific, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: Asia-Pacific, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: China, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: China, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: China, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: India, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: India, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: India, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: Japan, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: Japan, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Japan, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Australia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Australia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Australia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Indonesia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Indonesia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Indonesia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: South Korea, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: South Korea, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: South Korea, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: Taiwan, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: Taiwan, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: Taiwan, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: South East Asia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: South East Asia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: South East Asia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: Western Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: Western Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: Western Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: UK, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: UK, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: UK, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: Germany, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: Germany, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: Germany, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: France, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: France, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: France, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: Italy, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: Italy, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: Italy, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Spain, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Spain, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Spain, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Eastern Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Eastern Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Eastern Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Russia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Russia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: Russia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: North America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: North America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: North America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: USA, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: USA, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: USA, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: Canada, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: Canada, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: Canada, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: South America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: South America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: South America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: Brazil, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: Brazil, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: Brazil, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Middle East, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Middle East, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Middle East, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Africa, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Africa, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Africa, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 96: Global Non-Alcoholic Steatohepatitis (NASH) Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 97: Global Non-Alcoholic Steatohepatitis (NASH) Market - Company Scoring Matrix

Figure 98: NGM Biopharmaceuticals Inc. Financial Performance

Figure 99: Novartis AG Financial Performance

Figure 100: AstraZeneca plc. Financial Performance

Figure 101: GlaxoSmithKline plc. Financial Performance

Figure 102: F. Hoffmann-La Roche AG Financial Performance

Figure 103: Global Non-Alcoholic Steatohepatitis (NASH) Market, Competitive Benchmarking (In USD Billions)

Figure 104: Global Non-Alcoholic Steatohepatitis (NASH) Market, Competitive Dashboard

Figure 105: Global Non-Alcoholic Steatohepatitis (NASH) Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 106: Global, Non-Alcoholic Steatohepatitis (NASH) Market Size Gain ($ Billion), Segmentation By Dosage Form, 2025 – 2030

Figure 107: Global, Non-Alcoholic Steatohepatitis (NASH) Market Size Gain ($ Billion), Segmentation By Product, 2025 – 2030

Figure 108: Global, Non-Alcoholic Steatohepatitis (NASH) Market Size Gain ($ Billion), Segmentation By Disease Cause, 2025 – 2030

Cold And Flu Supplements Market Insights: In-Depth Look at Growth Trends, Market Size, and Opportunities for 2025-2034

Cold Remedies Market Trends 2025-2034: Growth, Strategic Insights, and Opportunities Ahead

Cold, Cough, And Sore Throat Remedies Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Cold, Cough, And Sore Throat Remedies Market Forecast 2025–2034: Trends Reshaping Demand, Investment, and Innovation

Uncover TBRC’s strategic outlook on technological trends, regulatory factors, and market growth in transdermal drug delivery systems.

Explore forecast data, therapeutic advancements, and pipeline progress in TBRC’s Tuberous Sclerosis Drug Market report.

Gain insights into strategic developments and market forecasts for the tissue plasminogen activator market.

Explore the impact of innovative phytocine lines on the herbal medicine market in 2025.

Microcarrier Market Report 2026 - Global Outlook – By Product (Equipment, Consumables), By Microcarrier Type (Cationic Microcarriers, Collagen-Coated Microcarriers, Protein-Coated Microcarriers, Untreated Microcarriers, ...

Emollients Market Report 2026 - Global Outlook – By Type (Esters, Fatty Alcohols, Fatty Acids, Ethers, Silicones, Other Types), By Form (Solid, Liquid), By Application (Skin Care, Hair Care, Other Applications), By End U...

Beauty Devices Market Report 2026 - Global Outlook – By Type (Hair Care Devices, Facial Devices, Skin Care Devices, Eye Care Devices), By Gender (Female, Male), By End Users (Commercial Or Professional, Domestic Or Perso...

Heart Attack Diagnostic Market Report 2026 - Global Outlook – By Test Type (Electrocardiogram (ECG Or EKG), Blood Tests, Echocardiogram, Coronary Catheterization (Angiogram)), By Procedure (Invasive Procedure, Non-Invasi...

Frequently Asked Questions

What is the projected market size of the Non-Alcoholic Steatohepatitis (NASH) Market Report 2026 market by 2030?

The Non-Alcoholic Steatohepatitis (NASH) Market Report 2026 market was valued at $6.06 billion in 2025, increased to $8.04 billion in 2026, and is projected to reach $24.32 billion by 2030. request a sample here

What is the expected CAGR for the Non-Alcoholic Steatohepatitis (NASH) Market Report 2026 market during the forecast period 2025 - 2030?

The expected CAGR for the Non-Alcoholic Steatohepatitis (NASH) Market Report 2026 market during the forecast period 2025–2030 is 31.9%. request a sample here

What are the key factors driving the Non-Alcoholic Steatohepatitis (NASH) Market Report 2026 market?

Major growth driver of the market includes: The Growing Demand For NASH Treatment Amid Obesity Epidemic in the Non-Alcoholic Steatohepatitis (NASH) Market Report 2026 market. For further insights on this market, request a sample here

Which end-use segment are covered in the Non-Alcoholic Steatohepatitis (NASH) Market Report 2026 market report?

The non-alcoholic steatohepatitis (nash) market covered in this report is segmented –
1) By Dosage Form: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral Subsegments:
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms request a sample here

What is the anticipated growth trend for the Non-Alcoholic Steatohepatitis (NASH) Market Report 2026 market?

Major trend in this market includes: Innovative Therapeutic Approaches for Liver Health For further insights on this market, request a sample here.

Who are the key players in the Non-Alcoholic Steatohepatitis (NASH) Market Report 2026 market?

Major companies operating in the Non-Alcoholic Steatohepatitis (NASH) Market Report 2026 market are Major companies operating in the non-alcoholic steatohepatitis (nash) market are NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithK request a sample here.

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2025. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. request a sample here.

Book your 30 minutes free consultation with our research experts

Contact Us